Does Rabbit Antithymocyte Globulin (Thymoglobuline®) Have a Role in Avoiding Delayed Graft Function in the Modern Era of Kidney Transplantation?
Table 2
Randomized clinical trials of rATG versus IL-2RA induction in adult kidney transplant recipients. Induction and maintenance therapies were started after procedure on the day of transplantation unless otherwise stated.
Low or moderate immunological risk (including CIT ≤36 hours, PRA ≤25%, no T-cell cross-match)
100
rATG (dose adjusted based on CD2/CD3 count) CsA (started based on graft function) MMF Steroids
Basiliximab (2 x 20mg) Immediate CsA MMF Steroids
6% vs 14%†
Month 12: 8.0% vs 8.5% (n.s.)
Significantly more frequent CMV infections with rATG vs basiliximab
third treatment group comprised basiliximab with low-dose TAC, MMF, and steroid maintenance therapy (data not shown). p value provided. to basiliximab (2 x 20 mg) after withdrawal of daclizumab from the market. on duration of cold ischemia time and predefined donor/recipient risk factors. BPAR, biopsy-proven acute rejection; CIT, cold ischemia time; CMV, cytomegalovirus; CsA, cyclosporine; DCD, donation after circulatory death; DGF, delayed graft function; DSA, donor-specific antibodies; IL-2RA, interleukin-2 receptor antagonist; MMF, mycophenolate mofetil; n.s., not significant; PRA, panel reactive antibodies; rATG, rabbit antithymocyte globulin; TAC, tacrolimus.